Teva Pharmaceutical Industries Ltd Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd logoTeva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: TEVA
  • CUSIP:
Key Metrics:
  • Previous Close: $51.47
  • 50 Day Moving Average: $52.00
  • 200 Day Moving Average: $53.21
  • 52-Week Range: $48.01 - $66.55
  • Trailing P/E Ratio: 34.38
  • Foreward P/E Ratio: 8.66
  • P/E Growth: 1.72
  • Market Cap: $47.04B
  • Outstanding Shares: 914,000,000
  • Beta: 0.82
Additional Links:
Companies Related to Teva Pharmaceutical Industries Ltd:

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (?)
Ratings Breakdown: 5 Hold Ratings, 19 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $67.64 (31.41% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Leerink SwannReiterated RatingBuyView Rating Details
9/12/2016Oppenheimer Holdings Inc.Set Price TargetBuy$66.00View Rating Details
9/11/2016RBC Capital MarketsSet Price TargetBuy$71.00View Rating Details
9/12/2016Jefferies GroupSet Price TargetBuy$69.00View Rating Details
9/12/2016Morgan StanleySet Price TargetBuy$63.00View Rating Details
8/25/2016MizuhoReiterated RatingBuy$70.00 -> $64.00View Rating Details
8/25/2016Credit Suisse Group AGReiterated RatingNeutral$59.00 -> $51.63View Rating Details
8/15/2016GuggenheimReiterated RatingBuy$80.00View Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$55.00 -> $57.00View Rating Details
7/26/2016JPMorgan Chase & Co.Reiterated RatingOverweight$75.00View Rating Details
7/18/2016Maxim GroupReiterated RatingBuyView Rating Details
7/18/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
7/18/2016HSBCUpgradeHold -> BuyView Rating Details
7/17/2016Goldman Sachs Group Inc.Lower Price Target$70.00 -> $60.00View Rating Details
6/13/2016Citigroup Inc.Reiterated RatingBuy$75.00View Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/10/2016Deutsche Bank AGLower Price TargetBuy$80.00 -> $71.00View Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/12/2016Bank of America Corp.Reiterated RatingBuy$82.00View Rating Details
4/7/2016BTIG ResearchReiterated RatingBuy$77.00View Rating Details
3/31/2016Sanford C. BernsteinReiterated RatingOutperform$43.00 -> $50.00View Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00View Rating Details
2/21/2016ArgusReiterated RatingBuy$82.00 -> $75.00View Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00View Rating Details
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00View Rating Details
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
5/2/2015Cowen and CompanyReiterated RatingOutperform$100.00View Rating Details
4/24/2015GabelliReiterated RatingBuyView Rating Details
4/7/2015Barclays PLCBoost Price TargetOverweight$70.00 -> $75.00View Rating Details
3/31/2015CRT CapitalBoost Price TargetBuy$67.00 -> $70.00View Rating Details
1/20/2015Sterne Agee CRTSet Price TargetBuy$65.00View Rating Details
10/8/2014ING GroupInitiated CoveragePositiveView Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Current Year EPS Consensus Estimate: $5.26 EPS
Next Year EPS Consensus Estimate: $5.94 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Annual Dividend:$1.16
Dividend Yield:2.25%
Dividend Growth:13.00% (3 Year Average)
Payout Ratio:22.05% (Based on Current Year Consensus EPS Estimate)
19.53% (Based on Next Year Consensus EPS Estimate)
Track Record:3 Years of Consecutive Dividend Growth

Dividend History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
DateHeadline
News IconPattern to Follow: A Reversal for Teva Pharmaceutical Industries Ltd (ADR) Is Near. The Formed Inverse Head ... - Chester News (NYSE:TEVA)
www.chesterindependent.com - September 24 at 6:50 PM
News IconDrug Manufacturers – Other: Teva Pharmaceutical Industries Limited (NYSE:TEVA) Position of the day (NYSE:TEVA)
twincountynews.com - September 24 at 10:07 AM
wallstrt24.com logoStocks under Review - Walt Disney, (NYSE:DIS), Teva Pharmaceutical Industries, (NYSE:TEVA), PulteGroup, (NYSE ... - Wall Street 24 (NYSE:TEVA)
wallstrt24.com - September 23 at 7:01 PM
zacks.com logoTeva Reports Positive Phase III Tardive Dyskinesia Data (NYSE:TEVA)
www.zacks.com - September 23 at 9:55 AM
marketexclusive.com logoTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Unveils Successful AIM-TD Clinical Trial Results (NYSE:TEVA)
marketexclusive.com - September 23 at 9:55 AM
marketexclusive.com logoTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Unveils Successful AIM-TD Clinical Trial Results - Market Exclusive (NYSE:TEVA)
marketexclusive.com - September 23 at 9:55 AM
News IconDeal Watch: Teva and Regeneron Announce Fasinumab Collaboration (NYSE:TEVA)
www.jdsupra.com - September 22 at 7:18 PM
4-traders.com logoTeva Pharmaceutical Industries : Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) (NYSE:TEVA)
www.4-traders.com - September 22 at 7:18 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA) from Drug Manufacturers – Other – Todays Top Gains (NYSE:TEVA)
twincountynews.com - September 22 at 7:18 PM
nasdaq.com logoTeva Reports Positive Top-Line Data From Second Phase III Study Of SD-809 (NYSE:TEVA)
www.nasdaq.com - September 22 at 10:04 AM
businesswire.com logoTeva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) (NYSE:TEVA)
www.businesswire.com - September 22 at 10:04 AM
4-traders.com logoTeva Pharmaceutical Industries : Huntington Disease Drug Meets Primary Endpoint (NYSE:TEVA)
www.4-traders.com - September 22 at 10:04 AM
marketexclusive.com logoTeva Pharmaceutical Industries Ltd (NYSE:TEVA), Perrigo And Sun Pharma To Bid For Dem Unit Of Bayer (NYSE:TEVA)
marketexclusive.com - September 22 at 10:04 AM
News IconGilead Sciences, Inc. (NASDAQ:GILD) & Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) News Recap - Money News (NYSE:TEVA)
www.newsismoney.com - September 22 at 10:04 AM
News IconAnalysts' Recommendations Stocks Watch List: Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) & Red Hat Inc ... - Money News (NYSE:TEVA)
www.newsismoney.com - September 22 at 10:04 AM
bloomberg.com logoBayer's Dermatology Unit Sale Said to Attract Teva and Perrigo - Bloomberg (NYSE:TEVA)
www.bloomberg.com - September 22 at 10:04 AM
News IconLeading stocks in today’s market: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
twincountynews.com - September 21 at 11:44 AM
streetinsider.com logoTeva Pharma (TEVA) Announces Positive Results from Pridopidine Phase 2 in Huntington Disease - StreetInsider.com (NYSE:TEVA)
www.streetinsider.com - September 20 at 9:41 AM
News IconStocks Making Notable Moves: Teva Pharmaceutical Industries Limited (NYSE:TEVA), Coherus Biosciences, Inc ... - Street Wise Report (press release) (blog) (NYSE:TEVA)
streetwisereport.com - September 20 at 9:41 AM
News IconHC Stocks Highlights! Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Clovis Oncology Inc (NASDAQ:CLVS) - share market updates (press release) (NYSE:TEVA)
sharemarketupdates.com - September 20 at 9:41 AM
seekingalpha.com logoTeva and Regeneron ink deal to develop fasinumab - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - September 20 at 9:41 AM
News IconRegeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain (NYSE:TEVA)
security.itbusinessnet.com - September 20 at 9:41 AM
rttnews.com logoRegeneron Pharma And Teva Pharma Reach Agreement To Commercialize Fasinumab (NYSE:TEVA)
www.rttnews.com - September 20 at 9:41 AM
finance.yahoo.com logoTeva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain (NYSE:TEVA)
finance.yahoo.com - September 20 at 9:41 AM
News IconTeva’s Trial Results Finds Drug Could Slow Huntington’s Disease (NYSE:TEVA)
jewishbusinessnews.com - September 19 at 7:34 PM
News IconHigh Market Cap Stock of the Day – Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
twincountynews.com - September 19 at 7:34 PM
News IconUS FDA approves Bayer contraceptive device Kyleena (NYSE:TEVA)
www.channelnewsasia.com - September 19 at 10:28 AM
News IconTrial finds Teva drug could slow Huntington's disease (NYSE:TEVA)
www.globes.co.il - September 19 at 10:28 AM
nasdaq.com logoTeva Pharma Reports Encouraging Results From Exploratory Phase 2 PRIDE-HD Study (NYSE:TEVA)
www.nasdaq.com - September 19 at 10:28 AM
4-traders.com logoTeva Pharmaceutical Industries : Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease (NYSE:TEVA)
www.4-traders.com - September 19 at 10:28 AM
finance.yahoo.com logo7:00 am Teva Pharma announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease; Pridopidine Demonstrates Slowing of Progression of Huntington Disease in PRIDE-HD Study as Measured by Total Functio (NYSE:TEVA)
finance.yahoo.com - September 19 at 10:28 AM
finance.yahoo.com logoTeva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease (NYSE:TEVA)
finance.yahoo.com - September 19 at 10:28 AM
News IconW.Va. ranks 18th in pharmaceutical companies' contributions to lawmakers (NYSE:TEVA)
www.register-herald.com - September 18 at 7:02 PM
News IconTeva and Intel partner to tackle Huntington’s disease (NYSE:TEVA)
www.opptrends.com - September 17 at 7:02 PM
businesswire.com logoTeva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for ... - Business Wire (press release) (NYSE:TEVA)
www.businesswire.com - September 17 at 7:02 PM
News IconTeva Pharma introduces generic Cubicin in US market (NYSE:TEVA)
pharmabiz.com - September 17 at 9:58 AM
News IconTeva, Intel to develop wearable tech for Huntington's disease (NYSE:TEVA)
www.channelnewsasia.com - September 16 at 11:14 AM
finance.yahoo.com logoTeva/Intel Tie up for Huntington's Disease Technology Platform (NYSE:TEVA)
finance.yahoo.com - September 16 at 11:14 AM
News IconIs Teva Pharmaceutical Industries Limited (NYSE:TEVA), a large market cap stock a smart buy? (NYSE:TEVA)
twincountynews.com - September 16 at 11:14 AM
News IconHC Stocks Overview! Teva Pharmaceutical Industries Ltd (TEVA), Celgene Corporation (NASDAQ:CELG) - share market updates (press release) (NYSE:TEVA)
sharemarketupdates.com - September 16 at 11:14 AM
News IconStocks Cheering Investors with Mouthwatering Facts: Teva Pharmaceutical Industries Limited (NYSE:TEVA), Alexion ... - Street Wise Report (press release) (blog) (NYSE:TEVA)
streetwisereport.com - September 16 at 11:14 AM
News IconTeva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) & Prudential Financial Inc (NYSE:PRU) UPDATE ON U.S ... - Money News (NYSE:TEVA)
www.newsismoney.com - September 16 at 11:14 AM
finance.yahoo.com logoIntel and Teva Partner on Cloud-based Healthcare Solutions (NYSE:TEVA)
finance.yahoo.com - September 16 at 11:14 AM
reuters.com logoTeva, Intel to develop wearables to monitor Huntington's disease - Reuters UK (NYSE:TEVA)
uk.reuters.com - September 15 at 7:46 PM
seekingalpha.com logoTeva's Transformation Reveals A Generics Market In Turmoil - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - September 15 at 7:46 PM
News IconTeva, Intel to develop wearable technology for Huntington's disease - Yahoo News (NYSE:TEVA)
www.yahoo.com - September 15 at 7:46 PM
News IconTeva, Intel to develop wearable technology for Huntington's disease (NYSE:TEVA)
www.channelnewsasia.com - September 15 at 7:46 PM
tmcnet.com logoNational Business Group on Health Honors Teva Pharmaceuticals with Best Employers for Healthy Lifestyles® Award (NYSE:TEVA)
www.tmcnet.com - September 15 at 11:22 AM
News IconTeva, Intel join forces to monitor Huntington disease (NYSE:TEVA)
www.timesofisrael.com - September 15 at 11:22 AM
businesswire.com logoTeva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous Measurement & Analysis of Huntington Disease Symptoms in Collaboration with Intel (NYSE:TEVA)
www.businesswire.com - September 15 at 11:22 AM

Social

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff